Net income of Neurocrine Biosciences under GAAP for the 3 months of 2022 was $13.9 million, down 2.3 times from $32.1 million in the previous year. Revenue increased 31.3% to $310.6 million compared to $236.6 million a year earlier.

Neurocrine Biosciences' GAAP net income for 2021 was $89.6 million, down 4.5 times from $407.3 million in the previous year. Revenue increased 8.4% to $1.134 billion from $1.046 billion a year earlier.

Neurocrine Biosciences' GAAP net income for 9M 2021 was $96.9 million, up 63.1% from $59.4 million in the previous year. Revenue increased 2.9% to $821.5 million from $798 million a year earlier.

Neurocrine Biosciences' GAAP net income for the six months of 2021 was $74.4 million, down 36.4% from $117 million in the previous year. Revenue decreased 2.6% to $525.5 million from $539.5 million a year earlier.